SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Venus Remedies - Quaterly Results

30 Jan 2023 Evaluate
A decrease in the sales to Rs. 1094.50 millions was observed for the quarter ended December 2022. The sales stood at Rs. 1174.40 millions during the similar quarter previous year.Net profit of the cmpany stood at Rs. 26.10 millions for the quarter ended December 2022 a decline of -66.75% from Rs. 78.50 millions  in the same quarter last year.Operating Profit reported a sharp decline to 108.30 millions from 153.00 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 1094.50 1174.40 -6.80 3891.30 4469.30 -12.93 5751.81 5146.23 11.77
Other Income 37.50 10.70 250.47 69.30 59.60 16.28 84.29 177.62 -52.54
PBIDT 108.30 153.00 -29.22 474.30 674.70 -29.70 772.50 646.25 19.54
Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 127.26 -100.00
PBDT 108.30 153.00 -29.22 474.30 674.70 -29.70 772.50 753.41 2.53
Depreciation 69.70 84.00 -17.02 233.10 252.20 -7.57 325.80 342.80 -4.96
PBT 38.60 69.00 -44.06 241.20 422.50 -42.91 446.70 410.61 8.79
TAX 12.50 -9.50 -231.58 26.90 -43.19 -162.28 -43.16 -132.12 -67.33
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 26.10 78.50 -66.75 214.30 465.69 -53.98 489.86 542.73 -9.74
Equity 133.70 133.70 0.00 133.70 133.70 0.00 133.67 123.42 8.30
PBIDTM(%) 9.89 13.03 -24.05 12.19 15.10 -19.26 13.43 12.56 6.95

Venus Remedies Share Price

1735.10 31.00 (1.82%)
10-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1935.25
Dr. Reddys Labs. 1245.50
Cipla 1438.75
Zydus Lifesciences 1150.50
Lupin 2496.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: